Key Takeaways CHMP recommends EU approval of Dupixent for chronic spontaneous urticaria in patients 12 and above.Phase III studies showed Dupixent reduced itch, hives and improved disease control.Dupixent sales hit EUR 7.3B in H1 2025, with Sanofi projecting about EUR 22B in sales by 2030.Sanofi (SNY) and partner Regeneron (REGN) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of Dupixent (dupilumab) in ...